ESPAÑOL ENGLISH

Rodríguez Abreu, Delvys

Publicaciones

All

Articles

Conference Papers

Annotation

Lecture

Others

Type

36 artículo
6 actas de congresos

By researcher

By affiliation

Title Issue Date
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study Boyer, Michael; Hui, Rina; Urban, Damien; Clingan, Philip; Su, Wu Chou, et al Issued date: 2024 DOI: 10.1186/s12885-022-10427-4 Source: BMC Cancer[EISSN 1471-2407],v. 23 (Suppl 1), (Julio 2024) SJR: 1,087 - Q2 JCR: 3,4 - Q2 SCIE MIAR ICDS: 10,8 Artículo
Alteration of bone quality and prevalence of fragility fractures in patients with breast cancer treated with aromatase inhibitors. A case-control study Gómez De Tejada Romero, Mª Jesús ; Murias Henríquez, Carmen Gloria ; Rodríguez Abreu, Delvys ; de la Rosa-Fernández, Frank; Suárez-Ramírez, Nerea, et al Issued date: 2024 DOI: 10.20960/RevOsteoporosMetabMiner.00054 Source: Revista de Osteoporosis y Metabolismo Mineral[ISSN 1889-836X],v. 16 (2), p. 48-55, (Abril 2024) SJR: 0,174 - Q4 ESCI MIAR ICDS: 9,6 ERIH PLUS Artículo
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial Spicer, Jonathan D.; Garassino, Marina C.; Wakelee, Heather; Liberman, Moishe; Kato, Terufumi, et al Issued date: 2024 DOI: 10.1016/S0140-6736(24)01756-2 Source: Lancet[ISSN 0140-6736],v. 404 (10459), p. 1240-1252, (Septiembre 2024) SJR: 12,113 - Q1 JCR: 98,4 - Q1 SCIE MIAR ICDS: 11,0 Artículo
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy Weiss, Sarah A.; Sznol, Mario; Shaheen, Montaser; Berciano-Guerrero, Miguel-Angel; Couselo, Eva Munoz, et al Issued date: 2024 DOI: 10.1158/1078-0432.CCR-23-0475 Source: Clinical Cancer Research [ISSN 1078-0432], v. 30 (1), p. 74-81, (Enero 2024). SJR: 4,623 - Q1 JCR: 10,4 - Q1 SCIE MIAR ICDS: 10,9 Artículo
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer Arriola, Edurne; de Castro, Javier; Garcia-Campelo, Rosario; Bernardez, Beatriz; Bernabe, Reyes, et al Issued date: 2024 DOI: 10.1007/s40261-024-01379-7 Source: Clinical Drug Investigation [ISSN 1173-2563], (Julio 2024) SJR: 0,68 - Q2 JCR: 2,9 - Q2 SCIE Artículo
Influence of serum uric acid on bone and fracture risk in postmenopausal women Gomez de Tejada Romero, Maria-Jesus; Murias Henríquez, Carmen Gloria ; Saavedra-Santana, Pedro ; Sablón González, Nery ; Rodríguez Abreu, Delvys , et al Issued date: 2024 DOI: 10.1007/s40520-024-02819-2 Source: Aging Clinical And Experimental Research [ISSN 1594-0667], v. 36, 156, (Agosto 2024) SJR: 1,005 - Q2 JCR: 3,4 - Q2 SCIE MIAR ICDS: 10,8 Artículo
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up Gadgeel, Shirish M.; Rodríguez Abreu, Delvys ; Halmos, Balazs; Garassino, Marina C.; Kurata, Takayasu, et al Issued date: 2024 DOI: 10.1016/j.jtho.2024.04.011 Source: Journal of Thoracic Oncology[ISSN 1556-0864], (Abril 2024) SJR: 7,879 - Q1 JCR: 21,1 - Q1 SCIE MIAR ICDS: 10,7 Artículo
Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC) Garassino, Marina Chiara; Wakelee, Heather A.; Spicer, Jonathan; Liberman, Moishe; Kato, Terufumi, et al Issued date: 2024 Source: Journal Of Clinical Oncology[ISSN 0732-183X],v. 42 (16) sup. S, Abstract 8012, (Junio 2024) SJR: 10,639 - Q1 JCR: 42,1 - Q1 SCIE MIAR ICDS: 11,0 Actas de congresos
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up Gadgeel, Shirish M.; Rodríguez Abreu, Delvys ; Halmos, Balazs; Garassino, Marina C.; Kurata, Takayasu, et al Issued date: 2024 DOI: 10.1016/j.jtho.2024.04.011 Source: Journal Of Thoracic Oncology [ISSN 1556-0864], v. 19 (8), p. 1228-1241, (Agosto 2024). SJR: 7,879 - Q1 JCR: 21,1 - Q1 SCIE MIAR ICDS: 10,7 Artículo
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer Provencio Pulla, Mariano; Pérez Parente, Diego; Olson, Sara; Ruiz Gracia, Pedro; Vilas, Esther, et al Issued date: 2024 DOI: 10.1007/s12094-023-03362-8 Source: Clinical & translational oncology [ISSN 1699-048X], v. 26 (6), p. 1384-1394, (2024). SJR: 0,837 - Q2 JCR: 2,8 - Q2 SCIE MIAR ICDS: 10,8 Artículo
Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry Candal Pedreira, Cristina; Ruano Raviña, Alberto; Calvo de Juan, Virginia; Cobo Dols, Manuel; Cantero, Alexandra, et al Issued date: 2024 DOI: 10.1016/j.arbres.2024.07.006 Source: Archivos de bronconeumología: Organo oficial de la Sociedad Española de Neumología y Cirugía Torácica SEPAR y la Asociación Latinoamericana de Tórax ( ALAT )[ISSN 0300-2896], v. 60 (2), p. 38-45 SJR: 0,464 - Q3 JCR: 8,7 - Q1 SCIE MIAR ICDS: 11,0 Artículo
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer Felip, Enriqueta; Metro, Giulio; Soo, Ross A.; Wolf, Juergen; Solomon, Benjamin J., et al Issued date: 2024 DOI: 10.1016/j.ejca.2024.114182 Source: European Journal Of Cancer[ISSN 0959-8049],v. 208, (Septiembre 2024) SJR: 2,501 - Q1 JCR: 7,6 - Q1 Artículo
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort Remon, J.; Auclin, E.; Zubiri, L.; Schneider, S.; Rodríguez Abreu, Delvys , et al Issued date: 2024 DOI: 10.1016/j.esmoop.2024.103004 Source: Esmo Open [eISSN 2059-7029] ,v. 9 (5), (Mayo 2024) SJR: 2,498 - Q1 JCR: 7,1 - Q1 ESCI MIAR ICDS: 10,2 Artículo
Advanced non‑squamous NSCLC with no actionable oncogenic driver in Spain: a cross‑sectional descriptive analysis of data from the Thoracic Tumor Registry Carcereny Costa, Enric; Rodríguez Abreu, Delvys ; Lopez Castro, R.; Franco Pérez, Fernando Fabio; Guirado, María, et al Issued date: 2024 DOI: 10.1007/s12094-024-03511-7 Source: Clinical & translational oncology[ISSN 1699-048X],v. 26 (12), p. 3218-3225 (Junio 2024) Artículo
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations Rodríguez Abreu, Delvys ; Bosch-Barrera, Joaquim; Gray, Jhanelle E.; Ahn, Myung Ju; Johnson, Melissa, et al Issued date: 2024 DOI: 10.1016/j.cllc.2023.12.010 Source: Clinical Lung Cancer [ISSN 1525-7304], v. 25 (3), p. 274-279, (Mayo 2024). SJR: 1,263 - Q1 JCR: 3,3 - Q2 SCIE MIAR ICDS: 10,8 Artículo
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy Gómez Rueda, Ana; Taus, Álvaro; Álvarez Álvarez, Rosa; Bernabé-Caro, Reyes; Chara, Luis, et al Issued date: 2024 DOI: 10.1007/s12094-024-03404-9 Source: Clinical & translational oncology [ISSN 1699-048X], v. 26 (7), p. 1779-1789, (2024). SJR: 0,837 - Q2 JCR: 2,8 - Q2 SCIE MIAR ICDS: 10,8 Artículo
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC Garassino, Marina C.; Gadgeel, Shirish; Novello, Silvia; Halmos, Balazs; Felip, Enriqueta, et al Issued date: 2023 DOI: 10.1016/j.jtocrr.2022.100431 Source: Jto Clinical And Research Reports [2666-3643],v. 4 (1), (Enero 2023) SJR: 1,321 - Q1 Artículo
Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab plus chemotherapy in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial. Felip, Enriqueta; Aix, Santiago Ponce; Bar, Jair; Esteban, Emilio; Rodríguez Abreu, Delvys , et al Issued date: 2023 Source: Journal Of Clinical Oncology [ISSN 0732-183X], v. 42 (16) sup. S, Abstract 8578, (Junio 2024). SJR: 10,639 - Q1 JCR: 42,1 - Q1 SCIE MIAR ICDS: 11,0 Actas de congresos
Effects of ozone therapy on anxiety and depression in patients with refractory symptoms of severe diseases: a pilot study Clavo Varas,Bernardino ; Cánovas-Molina, Angeles; Díaz-Garrido, Juan A.; Cañas, Silvia; Ramallo Fariña, Yolanda , et al Issued date: 2023 DOI: 10.3389/fpsyg.2023.1176204 Source: Frontiers in Psychology[EISSN 1664-1078],v. 14:1176204, (Agosto 2023) SJR: 0,8 - Q2 JCR: 3,8 - Q1 SSCI MIAR ICDS: 10,5 ERIH PLUS Artículo
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer Wakelee, H; Liberman, M; Kato, T; Tsuboi, M; Lee, SH, et al Issued date: 2023 DOI: 10.1056/NEJMoa2302983 Source: New England Journal of Medicine [0028-4793], v. 389, pp. 491-503 (agosto 2023) SJR: 20,544 - Q1 JCR: 96,3 - Q1 SCIE MIAR ICDS: 11,0 Artículo